



Crescendo Biologics shortlisted for Lifestars Awards 2018

Cambridge, UK, 20 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, is pleased to have been shortlisted for two Lifestars Awards.

The categories are:

- **EU Private Finance Raise of the Year**
- **EU Private Company of the Year**

Bringing together over 500 life science leaders, investors, and deal makers, the Lifestars Awards celebrates the innovations, game-changing deals and the people that have advanced the industry over the last 12 months.

Crescendo has had a successful year so far, transitioning into a class-leading developer of multi-functional Humabody® therapeutics. It closed its Series B financing round in April, which raised \$70m and added new top tier European and Asian investors to its existing investor base. Investors included Andera Partners (formerly Rothschild), Sofinnova Partners, Takeda Ventures, Quan Capital and IP Group. This financing round was, at the time, the largest European Series B in 2018.

Outside of its Series B raise, Crescendo also reached its first two major milestones in its multi-programme collaboration with Takeda ahead of time, and signed a licensing agreement with Zai Lab. In addition to this, Crescendo has continued to build a truly world class leadership team by hiring top-tier management and non-executive directors. The latest to join was Dr Pavel Pisa, ex-Head of Translational Medicine in Immunology for Roche, who will act as Crescendo's Chief Medical Officer.

The Lifestars Awards, in association with Jefferies, is being held on the evening of the LSX (formerly known as Biotech and Money) and Jefferies Inv€\$tival showcase. It is the signature networking function during the Jefferies Annual Healthcare conference in London, Europe's largest healthcare investment banking conference.

Details of the awards ceremony are as follows:

Lifestars Awards 2018

Date: Tuesday 13 November 2018, from 18.00

Venue: City Central at the HAC, Artillery Garden, Chiswell Street, London, EC1Y 4TW

For more information: <https://www.lsxleaders.com/lifestars-awards>

-Ends-



For more information, please contact:

Crescendo Biologics

Dr Peter Pack, CEO

+ 44 (0)1223 497140

info@crescendobiologics.com

For Media:

Instinctif Partners for Crescendo Biologics

Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell

+ 44 (0)20 7457 2020

crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V_H). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.